abstract |
Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C max of MTX between 5% and 50% of the C max of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX. |